stem cells

While most investors try to follow bubbles or pick over popular stocks for a little bit of profit, these undervalued companies may be poised for a bit of growth.

Stem cell research is still too hot for most investors, but NeoStem is starting to change that, thanks to some unexpected events. Among them are the Catholic Church's surprising embrace of NeoStem's research and NeoStem's foothold in China's vast health care market.

Companies involved in researching medical techniques using stem cells saw shares tumble across the board Tuesday, a day after a federal court ruled to block government funding for stem cell research.

StemCells Inc. shares jumped some 14% after the company reported new preclinical data showing its proprietary human neural stem cells restore lost motor function in mice long after their spinal cord injuries.

An unlicensed Las Vegas doctor who allegedly duped chronically ill patients into paying him for an illegal procedure -- implanting stem cells in their bodies with promises to cure irreversible diseases -- faces fines and as many as 20 years in prison. A yearlong investigation by the U.S. Food and...

For investors on the hunt for groundbreaking technologies, stem cell therapies looked promising. But while the world waited for new treatments, Wall Street lost interest. Now, the science is accelerating, but stock prices haven't caught up.

Long an old-line drug company, Pfizer is looking increasingly like a new biotech these days, especially after licensing a stem cell therapy. Athersys' MultiStem is a therapy that consists of a special class of stem cells obtained from the bone marrow of healthy, adult donors to treat inflammatory bowel disease.

It's not easy being first. Biotech company Geron (GERN) had to wait more than a year before getting the green light from federal regulators in January to begin the first study using human embryonic stem cell-based therapies in humans. The early-stage trial is looking at the safety of its drug...

On Monday, President Barack Obama signed an order lifting restrictions on federal funding of human embryonic stem cell research. Despite many beliefs to the contrary, no ban on stem cell research exists; only a ban on its public funding. In 1996 Congress banned public funding on the creation of new...

Choked for funding in recent years, stem cell researchers had some encouraging news over the weekend. On "Fox News Sunday," Top Obama aide David Axelrod confirmed that the president is expected to act soon on a campaign pledge to lift a federal spending ban on embryonic stem cell research. The move...